|

Zeprumetostat Clinical Trials

2 actively recruiting trials

Also known as: SHR2554

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

  • Rong Tao1
  • Institute of Hematology & Blood Diseases Hospital, China1

Indications

  • Cancer2
  • Relapsed or Refractory NK/T-Cell Lymphoma1
  • NK/T-cell Lymphoma1
  • Extranodal NK/T-cell Lymphoma1
  • Follicular Lymphoma1

Other2 trials

Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma
Phase 2
Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.